Current
—
5-Year Average
—
All-Time High
—
All-Time Low
—
P/FCF Ratio daily chart for Revolution Medicines (RVMD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/FCF ratio is not shown for periods when TTM free cash flow was negative.
Historical P/FCF Ratio for Revolution Medicines (RVMD) from 2019 to 2025
| 2025 | $15.14B | −$913.73M | — | — | |
| 2024 | $7.34B | −$567.74M | — | — | |
| 2023 | $4.05B | −$358.30M | — | — | |
| 2022 | $2.12B | −$235.22M | — | — | |
| 2021 | $1.86B | −$153.71M | — | — | |
| 2020 | $2.63B | −$103.00M | — | — | |
| 2019 | $1.05B | −$52.20M | — | — |
- 2025—
- 2024—
- 2023—
- 2022—
- 2021—
- 2020—
- 2019—
About P/FCF Ratio at Revolution Medicines (RVMD)
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Revolution Medicines (RVMD), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric